|

Tafolecimab Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Pipeline

Phase 2: 2

Top Sponsors

  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Jinghui Wang1

Indications

  • Lung Cancer2
  • Cancer2
  • Extensive Disease Small Cell Lung Cancer1
  • Extensive Stage Lung Small Cell Cancer1
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)1

Other2 trials

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
Phase 2
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.